Related Experiment Video

Updated: Jun 14, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

No small matter: microRNAs - key regulators of cancer stem cells

Qing Ji, David Karnak, Ping Hao

    International Journal of Clinical and Experimental Medicine
    |April 7, 2010
    PubMed

    Insights

    MicroRNAs (miRNAs) are key epigenetic regulators in cancer stem cells. Restoring the balance of tumor suppressor and oncogenic miRNAs may offer a novel therapy for cancers by modulating cancer stem cell pathways.

    Area of Science:

    • Molecular Biology
    • Epigenetics
    • Cancer Stem Cell Biology

    Background:

    • MicroRNAs (miRNAs) regulate gene expression and are crucial for stem cell self-renewal and differentiation.
    • Emerging evidence suggests miRNAs are critical in cancer stem cells (CSCs), influencing their epigenetic regulation.
    • An imbalance between oncogenic and tumor suppressor miRNAs may lead to CSC dysregulation, promoting self-renewal, survival, and therapeutic resistance.

    Purpose of the Study:

    • To explore the role of miRNAs in the epigenetic regulation of cancer stem cells.
    • To investigate how miRNA imbalance contributes to CSC self-renewal, survival, and chemo/radiotherapy resistance.
    • To propose miRNA-based therapeutic strategies for human cancers by targeting CSCs.

    Main Methods:

    • Review of emerging evidence on miRNA function in stem cells and cancer stem cells.
    • Analysis of the impact of oncogenic vs. tumor suppressor miRNA imbalance on CSC characteristics.
    • Postulation of therapeutic approaches involving the restoration of miRNA balance.

    Main Results:

    • MiRNAs are key epigenetic regulators in CSCs, impacting self-renewal and differentiation.
    • Dysregulation of miRNAs contributes to excessive CSC self-renewal, survival, and treatment resistance.
    • Restoring miRNA balance is hypothesized to correct CSC dysregulation.

    Conclusions:

    • Modulating the balance of tumor suppressor and oncogenic miRNAs can correct CSC pathway dysregulation.
    • Restoring key regulatory pathways by balancing miRNAs may improve therapeutic responses in cancer.
    • Targeting miRNAs offers a potential novel molecular therapy for human cancers by modulating CSCs.
    Keywords:
    cancermicroRNAsoncogeneregulatorsstem cells

    More Related Videos

    MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

    MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

    Published on: October 7, 2025

    CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

    CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

    Published on: April 25, 2022

    Related Concept Videos

    Cancer Stem Cells and Tumor Maintenance02:40

    Cancer Stem Cells and Tumor Maintenance

    Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
    Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
    Cancer Stem Cells and Tumor Maintenance02:40

    Cancer Stem Cells and Tumor Maintenance

    Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
    Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...